"Health Canada's approval of ONPATTRO underscores our commitment to deliver innovative medicines with the potential to transform the lives of patients suffering from hATTR amyloidosis with polyneuropathy," says Jeff Miller, Country Manager, Alnylam Canada. "It marks a major milestone in Alnylam's history, as the company's first treatment approved in Canada, but we believe this is just the beginning. Our vision is to harness the power of RNAi therapeutics to increase the number of treatment options available for patients with serious, life-threatening rare diseases where there are currently limited or no available treatment options. We take pride in working with the medical and patient community to increase awareness, enable diagnosis and provide important education and support services."